- P&G, Reckitt Benckiser among 2011 Product of the Year USA award recipients
- Reckitt Benckiser acquires LiceMD brand
- Reckitt Benckiser pursuit of Schiff Nutrition a success; companies sign definitive merger agreement
- Report: Bayer will not raise offer for Schiff Nutrition as negotiations continue
- Reckitt Benckiser ups the ante for Schiff business with a 23.5% premium to Bayer buyout offer
SLOUGH, England — Reckitt Benckiser will be launching a product for nighttime cold and flu relief in both liquid and tablet form, the company's CEO told investors Monday morning.
"Just a few years ago, Mucinex was only a cough and congestion brand, albeit one which enjoyed trust and loyalty of its consumers," commented Rakesh Kapoor, Reckitt CEO, executive director and member of the nomination committee. "Now we took that equity and extended it to mainstream cold and flu with the launch of Fast-Max first in liquids and then in caplets," he said.
"We are now launching a powerful product for nighttime cold and flu relief in both liquids and tablet form. Now just for perspective, nighttime is a $600 million market in the U.S. Mucinex Fast-Max is stronger than any other OTC nighttime product available to U.S. consumers because it contains an active for nasal congestion, which competition does not have."
Like this story? Find us on Facebook for more insight, analysis and the latest in drug store news. Join the conversation.